Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Stress Conditions Increase Vimentin Cleavage by Omi/HtrA2 Protease in Human Primary Neurons and Differentiated Neuroblastoma Cells.

Authors:
Bérangère Lucotte Mehdi Tajhizi Dareen Alkhatib Eva-Britt Samuelsson Birgitta Wiehager Sophia Schedin-Weiss Erik Sundström Bengt Winblad Lars O Tjernberg Homira Behbahani

Mol Neurobiol 2015 Dec 8;52(3):1077-1092. Epub 2014 Oct 8.

Karolinska Institutet, Department of Neurobiology, Care Sciences and Society (NVS), Center for Alzheimer Research, Division for Neurogeriatrics, Novum 5th floor, SE-141 57, Huddinge, Sweden.

Dysfunctional Omi/HtrA2, a mitochondrial serine protease, has been implicated in various neurodegenerative disorders. Despite the wealth of evidence on the roles of Omi/HtrA2 in apoptosis, little is known about its cytosolic targets, the cleavage of which could account for the observed morphological changes such as cytoskeletal reorganizations in axons. By proteomic analysis, vimentin was identified as a substrate for Omi/HtrA2 and we have reported increased Omi/HtrA2 protease activity in Alzheimer disease (AD) brain. Here, we investigated a possible link between Omi/HtrA2 and vimentin cleavage, and consequence of this cleavage on mitochondrial distribution in neurons. In vitro protease assays showed vimentin to be cleaved by Omi/HtrA2 protease, and proximity ligation assay demonstrated an increased interaction between Omi/HtrA2 and vimentin in human primary neurons upon stress stimuli. Using differentiated neuroblastoma SH-SY5Y cells, we showed that Omi/HtrA2 under several different stress conditions induces cleavage of vimentin in wild-type as well as SH-SY5Y cells transfected with amyloid precursor protein with the Alzheimer disease-associated Swedish mutation. After stress treatment, inhibition of Omi/HtrA2 protease activity by the Omi/HtrA2 specific inhibitor, Ucf-101, reduced the cleavage of vimentin in wild-type cells. Following altered vimentin filaments integrity by stress stimuli, mitochondria was redistributed in differentiated SH-SY5Y cells and human primary neurons. In summary, the findings outlined in this paper suggest a role of Omi/HtrA2 in modulation of vimentin filamentous structure in neurons. Our results provide important findings for understanding the biological role of Omi/HtrA2 activity during stress conditions, and give knowledge of interplay between Omi/HtrA2 and vimentin which might affect mitochondrial distribution in neurons.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12035-014-8906-3DOI Listing
December 2015

Publication Analysis

Top Keywords

omi/htra2 protease
16
omi/htra2
14
stress conditions
12
human primary
12
sh-sy5y cells
12
primary neurons
12
omi/htra2 vimentin
12
vimentin
10
protease activity
8
cleavage vimentin
8
distribution neurons
8
vimentin wild-type
8
mitochondrial distribution
8
stress stimuli
8
differentiated neuroblastoma
8
vimentin cleavage
8
role omi/htra2
8
stress
6
protease
6
neurons
6

Altmetric Statistics


Show full details
1 Total Shares
1 Tweets
1 Citations

Similar Publications

Mitochondrial serine protease Omi/HtrA2 accentuates brain ischemia/reperfusion injury in rats and oxidative stress injury in vitro by modulating mitochondrial stress proteins CHOP and ClpP and physically interacting with mitochondrial fusion protein OPA1.

Authors:
Hailong You Yao Jin Jinsong Kang Ying Mao Jing Su Liankun Sun Li Wang Hao Meng

Bioengineered 2020 12;11(1):1058-1070

Department of Pathophysiology, College of Basic Medical Sciences, Jilin University , Changchun, China.

Serine protease Omi/HtrA2, a member of the HtrA family, is closely related to the maintenance of mitochondrial integrity and participates in apoptosis but its role in cerebral ischemia/reperfusion (I/R) injury and cellular oxidative stress response remains unclear. In this study, we found that I/R injury resulted in a time-dependent increase in Omi/HtrA2 expression in rat brain tissue. Inhibition of Omi/HtrA2 significantly inhibited XIAP cleavage in HO-induced PC12 cells. Read More

View Article and Full-Text PDF
December 2020
Similar Publications

Acetaldehyde dehydrogenase 2 deficiency increases mitochondrial reactive oxygen species emission and induces mitochondrial protease Omi/HtrA2 in skeletal muscle.

Authors:
Yuka Wakabayashi Yuki Tamura Karina Kouzaki Naoki Kikuchi Kenji Hiranuma Kunitaka Menuki Takafumi Tajima Yoshiaki Yamanaka Akinori Sakai Keiichi I Nakayama Toshihiro Kawamoto Kyoko Kitagawa Koichi Nakazato

Am J Physiol Regul Integr Comp Physiol 2020 04 12;318(4):R677-R690. Epub 2020 Feb 12.

Graduate School of Health and Sport Science, Nippon Sport Science University, Tokyo, Japan.

Acetaldehyde dehydrogenase 2 (ALDH2) is an enzyme involved in redox homeostasis as well as the detoxification process in alcohol metabolism. Nearly 8% of the world's population have an inactivating mutation in the gene. However, the expression patterns and specific functions of ALDH2 in skeletal muscles are still unclear. Read More

View Article and Full-Text PDF
April 2020
Similar Publications

Heat shock factor 1-mediated transcription activation of Omi/HtrA2 induces myocardial mitochondrial apoptosis in the aging heart.

Authors:
Dan Liu Linguo Wu Ye Wu Xin Wei Wen Wang Suli Zhang Ming Yi Jing Li Huirong Liu Xinliang Ma

Aging (Albany NY) 2019 10 18;11(20):8982-8997. Epub 2019 Oct 18.

Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Background: Increased cardiac apoptosis is a hallmark of the elderly, which in turn increases the risk for developing cardiac disease. The overexpression of Omi/HtrA2 mRNA and protein contributes to apoptosis in the aged heart. Heat shock factor 1 (HSF1) is a transcription factor that binds to the promoter of Omi/HtrA2 in the aging myocardium. Read More

View Article and Full-Text PDF
October 2019
Similar Publications

Intrafamilial "DOA-plus" phenotype variability related to different OMI/HTRA2 expression.

Authors:
Filomena Napolitano Chiara Terracciano Giorgia Bruno Claudia Nesti Maria R Barillari Umberto Barillari Filippo M Santorelli Mariarosa A B Melone Teresa Esposito Simone Sampaolo

Am J Med Genet A 2020 01 14;182(1):176-182. Epub 2019 Oct 14.

Department of Advanced Medical and Surgical Sciences, 2nd Division of Neurology, Center for Rare Diseases and Inter University Center for Research in Neurosciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

Dominant Optic Atrophy and Deafness (DOAD) may be associated with one or more of the following disorders such as myopathy, progressive external ophthalmoplegia, peripheral neuropathy, and cerebellar atrophy ("DOA-plus"). Intra- and interfamilial variability of the "DOA-plus" phenotype is frequently observed in the majority of the patients carrying the same mutation in the OPA1 gene. We are describing two familial cases of "DOA-plus" carrying the same c. Read More

View Article and Full-Text PDF
January 2020
Similar Publications

p53 mediated transcription of Omi/HtrA2 in aging myocardium.

Authors:
Linguo Wu Dan Liu Ye Wu Xin Wei Zhaojia Wang Wen Wang Suli Zhang Hong Yang Ming Yi Huirong Liu

Biochem Biophys Res Commun 2019 11 19;519(4):734-739. Epub 2019 Sep 19.

Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China; Beijing Key Laboratory of Metabolic Disturbance Related Cardiovascular Disease, Beijing, 100069, China. Electronic address:

Aims: Omi/HtrA2 is a pro-apoptotic protein, increased mRNA and protein levels of Omi/HtrA2 in aging myocardium facilitates apoptosis and affects mitochondrial homeostasis. Our previous study found that p53 can bind to the Omi/HtrA2 promoter. The purpose of this study was to determine whether p53 participates in regulating the expression of Omi/HtrA2 in aging myocardium. Read More

View Article and Full-Text PDF
November 2019
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap